1. Home
  2. PSIX vs IBRX Comparison

PSIX vs IBRX Comparison

Compare PSIX & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PSIX

Power Solutions International Inc.

HOLD

Current Price

$66.07

Market Cap

2.0B

Sector

Industrials

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$2.23

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSIX
IBRX
Founded
1985
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.3B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PSIX
IBRX
Price
$66.07
$2.23
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
7
Target Price
$98.76
$9.71
AVG Volume (30 Days)
506.2K
11.5M
Earning Date
11-06-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
122.27
N/A
EPS
5.26
N/A
Revenue
$675,481,000.00
$82,555,000.00
Revenue This Year
$48.27
$667.18
Revenue Next Year
$14.25
$88.32
P/E Ratio
$11.97
N/A
Revenue Growth
54.78
1025.95
52 Week Low
$15.30
$1.83
52 Week High
$121.78
$4.27

Technical Indicators

Market Signals
Indicator
PSIX
IBRX
Relative Strength Index (RSI) 53.89 49.72
Support Level $60.49 $2.17
Resistance Level $62.26 $2.50
Average True Range (ATR) 3.76 0.16
MACD 2.25 0.02
Stochastic Oscillator 94.88 39.42

Price Performance

Historical Comparison
PSIX
IBRX

About PSIX Power Solutions International Inc.

Power Solutions International Inc is an America-based company that manufactures, distributes, and services power systems that run on nondiesel fuels, including natural gas, propane, and gasoline. The company's products are designed to meet emission standards imposed by environmental regulatory bodies like the Environmental Protection Agency. Its products are distributed to a wide range of industrial original equipment manufacturers that supply equipment to sectors including power generation, oil and gas, material handling, airport ground support, agricultural, turf, construction and irrigation. The company generates majority of its sales from United States.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: